State of the Science and Ethical Considerations for Preimplantation Genetic Testing for Monogenic Cystic Kidney Diseases and Ciliopathies
Whitney S. Thompson(Mayo Clinic), Christian Hanna(Mayo Clinic), Fouad T. Chebib(University Medical Center Groningen), Samir N. Babayev(Mayo Clinic), Ellen Bendel‐Stenzel(Mayo Clinic), Michelle L. McGowan(Mayo Clinic), Andrea G. Kattah(Mayo Clinic), Vicente E. Torres(Mayo Clinic in Arizona), Myra Wick, Neera K. Dahl(University Medical Center Groningen), Peter C. Harris(Mayo Clinic)
Cited by 14
Related Papers
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017
|Journal of the National Comprehensive Cancer Network|2016|660
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
|Kidney International|2015|602
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2020|507
Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis.
|The Journal of Experimental Medicine|1984|483